Alamar Biosciences, Inc. (California) (ALMR)
30.83
-0.93
(-2.93%)
USD |
NASDAQ |
Nov 13, 16:00
30.83
0.00 (0.00%)
After-Hours: 19:59
Alamar Biosciences Enterprise Value : 2.022B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 2.022B |
| November 11, 2026 | 2.012B |
| November 10, 2026 | 2.004B |
| November 09, 2026 | 2.028B |
| November 06, 2026 | 1.764B |
| November 05, 2026 | 1.685B |
| November 04, 2026 | 1.718B |
| November 03, 2026 | 1.915B |
| November 02, 2026 | 1.826B |
| October 30, 2026 | 1.941B |
| October 29, 2026 | 2.180B |
| October 28, 2026 | 2.198B |
| October 27, 2026 | 2.034B |
| October 26, 2026 | 1.927B |
| October 23, 2026 | 1.948B |
| October 22, 2026 | 1.880B |
| October 21, 2026 | 2.000B |
| October 20, 2026 | 1.772B |
| October 19, 2026 | 1.643B |
| October 16, 2026 | 1.572B |
| October 15, 2026 | 1.721B |
| October 14, 2026 | 1.578B |
| October 13, 2026 | 1.450B |
| October 12, 2026 | 1.500B |
| October 09, 2026 | 1.571B |
| Date | Value |
|---|---|
| October 08, 2026 | 1.616B |
| October 07, 2026 | 1.745B |
| October 06, 2026 | 2.057B |
| October 05, 2026 | 2.465B |
| October 02, 2026 | 2.203B |
| October 01, 2026 | 2.071B |
| September 30, 2026 | 2.183B |
| September 29, 2026 | 2.067B |
| September 28, 2026 | 2.064B |
| September 25, 2026 | 2.077B |
| September 24, 2026 | 2.105B |
| September 23, 2026 | 2.031B |
| September 22, 2026 | 2.106B |
| September 21, 2026 | 2.233B |
| September 18, 2026 | 2.220B |
| September 17, 2026 | 2.022B |
| September 16, 2026 | 1.840B |
| September 15, 2026 | 1.796B |
| September 14, 2026 | 1.744B |
| September 11, 2026 | 1.737B |
| September 10, 2026 | 1.728B |
| September 09, 2026 | 1.811B |
| September 08, 2026 | 1.880B |
| September 04, 2026 | 1.938B |
| September 03, 2026 | 1.923B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Personalis, Inc. | 1.565B |
| 10X Genomics, Inc. | 7.271B |
| Champions Oncology, Inc. | 71.90M |
| Medpace Holdings, Inc. | 17.79B |
| Avantor, Inc. | 13.81B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.34M |
| Revenue (Quarterly) | 33.54M |
| Total Expenses (Quarterly) | 46.89M |
| EPS Diluted (Quarterly) | -0.1921 |
| Gross Profit Margin (Quarterly) | 61.54% |
| Profit Margin (Quarterly) | -39.77% |
| Earnings Yield | -2.61% |
| Normalized Earnings Yield | -2.286 |